|Mr. Andrew D.C. LaFrence CPA, CPA||CFO & COO||106.07k||N/A||1963|
|Mr. Yung-Ping Yeh M.B.A., M.S., P.M.P.||Chief Innovation Officer & Director||210.33k||N/A||N/A|
|Dr. Robert J. Petcavich||Chief Science Advisor & Director||212.48k||N/A||1954|
|Mr. John A. Roberts M.B.A., MBA||Pres, CEO & Director||N/A||N/A||1959|
|Dr. Ralf Brandt||Pres of Discovery & Early Devel. Services||N/A||N/A||1967|
|Dr. Barb Jones Ph.D.||Sr. VP of External & Regulatory Affairs||N/A||N/A||N/A|
Vyant Bio, Inc. operates as a biotechnology drug discovery company. The company, through its subsidiary, StemoniX, develops and manufactures at-scale human induced pluripotent stem (iPS) cell-derived neural and cardiac screening platforms for drug discovery and development. StemoniX, through collaborations with drug discovery organizations, tests compounds in-house, creates cell-based disease models, and operationalizes custom human iPSC-derived disease models for high-throughput screening. The company, through its subsidiary, vivoPharm, offers proprietary preclinical test systems supporting clinical diagnostic offerings at early stages by the pharmaceutical industry, biotechnology companies, and academic research centers. vivoPharm specializes in conducting studies to guide drug development, starting from compound libraries and ending with a set of in vitro and in vivo data and reports, as needed for investigational new drug filings. The company is based in Cherry Hill, New Jersey.
Vyant Bio, Inc.’s ISS Governance QualityScore as of N/A is N/A. The pillar scores are Audit: N/A; Board: N/A; Shareholder Rights: N/A; Compensation: N/A.